Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy

Our objective was to examine whether delivery at 37 weeks of gestation alters adverse pregnancy outcomes in Latina patients with intrahepatic cholestasis of pregnancy (ICP). We conducted a retrospective chart review of Latina patients who delivered at our institution coded with ICP between 2000 and...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of perinatology Vol. 25; no. 6; p. 341
Main Authors Lee, Richard H, Kwok, Kay May, Ingles, Sue, Wilson, Melissa L, Mullin, Patrick, Incerpi, Marc, Pathak, Bhuvan, Goodwin, T Murphy
Format Journal Article
LanguageEnglish
Published United States 01.06.2008
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Our objective was to examine whether delivery at 37 weeks of gestation alters adverse pregnancy outcomes in Latina patients with intrahepatic cholestasis of pregnancy (ICP). We conducted a retrospective chart review of Latina patients who delivered at our institution coded with ICP between 2000 and 2007. During this time period it was our practice to offer delivery to patients with ICP at 37 weeks of gestation. Subjects were classified into three groups according to total bile acid (TBA) concentration: < 20 micromol/L (mild ICP), > or = 20 micromol/L and < 40 micromol/L (moderate ICP), and > or = 40 micromol/L (severe ICP). Meconium passage was observed in no births in patients with mild IC, but was found in 18% of deliveries with moderate/severe ICP. The risk of meconium passage increased linearly, with a 19.7% increased risk for each 10 mumol/L increase in TBA concentration ( P = 0.001). There was no association with higher TBA concentration and other adverse outcomes. There was no difference in adverse outcomes between moderate and severe ICP. We concluded that in our Latina population with ICP, an association existed between meconium passage and moderate/severe ICP. Delivering at 37 weeks was associated with a low risk of adverse outcomes due to ICP among all patients, including those with higher TBA concentrations.
ISSN:0735-1631
DOI:10.1055/s-2008-1078756